Last update :
22/01/2021
Anticancer drug   Bevacizumab  
Injection
Eye-drops
Stability in solutions Stability of mixtures Factors which affect stability Incompatibilities Route of administration References Pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Altuzan Turkey
Avastin Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Spain, Sweden, Switzerland, Tunisia, United Arab Emirates, United States of America, Venezuela
Bevax Argentina
Stability in solutions   Injection   Stability in solutions : Bevacizumab     
Container Solvent Concentration Temperature Storage Length of time References
Polyvinyl chloride Sodium chloride 0,9% 1,4 & 16.5 mg/ml 2-8°C Not specified
35 Day
4469 Biosimilar
Polyvinyl chloride Sodium chloride 0,9% 1.4 & 16.5 mg/ml 30°C Not specified
2 Day
4469 Biosimilar
Polyvinyl chloride Sodium chloride 0,9% 1.4 >> 16.5 mg/ml 2-30°C Not specified
48 Hour
4467
Manufacturer\'s stability data

Polyvinyl chloride Sodium chloride 0,9% 1.4 >> 16.5 mg/ml 2-8°C Not specified
30 Day
4467
Manufacturer\'s stability data

Polyolefine Sodium chloride 0,9% 1,4 & 16.5 mg/ml 2-8°C Not specified
35 Day
4469 Biosimilar
Polyolefine Sodium chloride 0,9% 1.4 & 16.5 mg/ml 30°C Not specified
2 Day
4469 Biosimilar
Polyolefine Sodium chloride 0,9% 1.4 >> 16.5 mg/ml 2-30°C Not specified
48 Hour
4467
Manufacturer\'s stability data

Polyolefine Sodium chloride 0,9% 1.4 >> 16.5 mg/ml 2-8°C Not specified
30 Day
4467
Manufacturer\'s stability data

Polyolefine Sodium chloride 0,9% 16 mg/ml 22°C Not specified
90 Day
2882
Level of evidence B+

Polyolefine Sodium chloride 0,9% 16 mg/ml 4°C Not specified
90 Day
2882
Level of evidence B+

Polyolefine Sodium chloride 0,9% 2 mg/ml 22°C Not specified
90 Day
2882
Level of evidence B+

Polyolefine Sodium chloride 0,9% 2 mg/ml 4°C Not specified
90 Day
2882
Level of evidence B+

Syringe polycarbonate None 25 mg/ml 2-8°C Not specified
180 Day
2661
Level of evidence A+

Polypropylen Syringe None 25 mg/ml 2-8°C Not specified
180 Day
2661
Level of evidence A+

Polypropylen Syringe None 25 mg/ml 4°C With or without light
90 Day
3265
Level of evidence B+

Polypropylen Syringe None 25 mg/ml 4°C Protect from light
90 Day
3312
Level of evidence B+


  Mentions Légales